Rxsight

Bull case

• RxSight is viewed positively because its differentiated light-adjustable lens platform is supported by strong premium-market penetration, with 1Q26 LAL sales of 27,472 units, roughly 10-11% share, even as revenue of $30.9M exceeded consensus and gross margin reached 76.1% on favorable product mix.
• The outlook also rests on signs that utilization can recover, with management noting encouraging trends in accounts using its commercial strategy, which could help drive a return to growth in 2H26 and support double-digit growth in the bull case.
• Although LDD placements fell to 20 and operating expenses rose to $17.8M, the expectation that cash burn improves as LALs make up a larger share of revenue, alongside reiterated 2026 revenue guidance of $120-135M, reinforces the long-term fundamental case.

Bear case

RxSight is facing a weaker-than-expected core business, as 2Q26 underlying revenue of $27M fell short of the $32M consensus and LAL sales and LDD placements both missed expectations, signaling softer adoption and utilization. Management’s cut to 2026 underlying revenue guidance to $110-120M from $120-135M, alongside expected operating expenses at the high end of $150-160M, suggests persistent pressure on profitability even with gross margin guidance lifted to 73-75%. Competitive trialing, likely from JNJ’s PureSee, limited adoption of the capital equipment-driven model, while the company’s $209M cash balance offers some cushion but does not offset the risk of further utilization declines, margin contraction, or a dilutive financing round.